Diagnostic Wandering in a Therapeutic Emergency: A Case Study of an AL Cardiac Amyloidosis Mimicking Tuberculosis
Published: 2022-12-23
Page: 366-370
Issue: 2022 - Volume 5 [Issue 1]
Karimou Bondabou Abdoul Wahab *
Faculty of Medicine and Pharmacy of Rabat, Unit of Pedagogy and Research of Cardiology, Morocco.
Oketokoun Arike Rachidath
Faculty of Medicine and Pharmacy of Rabat, Unit of Pedagogy and Research of Cardiology, Morocco.
Dib Hassan
Faculty of Medicine and Pharmacy of Rabat, Unit of Pedagogy and Research of Cardiology, Morocco.
Hamidi Mariyam
Faculty of Medicine and Pharmacy of Rabat, Unit of Pedagogy and Research of Cardiology, Morocco.
Fellat Nadia
Faculty of Medicine and Pharmacy of Rabat, Unit of Pedagogy and Research of Cardiology, Morocco.
Fellat Rokya
Faculty of Medicine and Pharmacy of Rabat, Unit of Pedagogy and Research of Cardiology, Morocco.
Cherti Mohamed
Faculty of Medicine and Pharmacy of Rabat, Unit of Pedagogy and Research of Cardiology, Morocco.
*Author to whom correspondence should be addressed.
Abstract
Background: Cardiac amyloidosis corresponds to a buildup of fibrillar proteins in the myocardium. It is characterized by non-specific signs that often lead to a late diagnosis, even though it is an emergency in some cases.
Objective: This case report emphasizes the very long route of care before the diagnosis of cardiac amyloidosis.
Case Presentation: A 62-year-old woman with a history of close contact exposure to tuberculosis presented to a peripheral health center with a chronic cough. After several examinations, the diagnosis of pleural tuberculosis was retained. After two months of specific treatment, the patient did not improve, which motivated the request for echocardiography which found signs suggestive of cardiac amyloidosis. The questioning and the clinical examination were repeated. This gave arguments to continue the investigation which led to the final diagnosis of light chain (AL) cardiac amyloidosis.
Discussion: The long route of care before diagnosis of cardiac amyloidosis worsens the prognosis because of the therapeutic delay. The patient often consults several specialists before arriving at the diagnosis. The presence of clinical signs called "red flags" associated with left ventricular hypertrophy should suggest cardiac amyloidosis. Cardiac MRI and biopsy of certain peripheral organs reduced the indication for endocardial biopsy for diagnostic purposes.
Conclusion: To improve the prognosis, every clinician must know the red flags of cardiac amyloidosis.
Keywords: Cardiac amyloidosis, pleural tuberculosis, multiple myeloma, cardiac MRI
How to Cite
Downloads
References
Baker KR. Light chain amyloidosis: Epidemiology, staging, and prognostication. Methodist DeBakey Cardiovasc J. 2022;18(2):27–35.
Hester LL, Gifkins DM, M Bellew K, Vermeulen J, Schecter JM, Strony J, et al. Diagnostic delay and characterization of the clinical prodrome in AL amyloidosis among 1523 US adults diagnosed between 2001 and 2019. Eur J Haematol. 2021;107(4):428‑35.
Lousada I, Maurer M, Warner M, Guthrie S, Hsu K, Grogan M. Amyloidosis research consortium cardiac amyloidosis survey: Results from patients with al and attr amyloidosis and their caregivers. J Am Coll Cardiol. 2018;71(11):A890–A890.
Kyriakou P, Mouselimis D, Tsarouchas A, Rigopoulos A, Bakogiannis C, Noutsias M, et al. Diagnosis of cardiac amyloidosis: A systematic review on the role of imaging and biomarkers. BMC Cardiovasc Disord. 2018; 18:221.
Choukair MO, Halawi A, Nehmeh A, Kazma H. Role of echocardiography in the diagnosis of light chain amyloidosis: A case report and review of literature. Cureus. 2020;12(11):e11377.
Shah O, Choh N, Shera T, Shera F, Gojwari T, Shaheen F, et al. Magnetic resonance imaging in cardiac amyloidosis: Unraveling the stealth entity. Int J Angiol Off Publ Int Coll Angiol Inc. 2022;31(1):40–47.
Garcia-Pavia P, Rapezzi C, Adler Y, Arad M, Basso C, Brucato A, et al. Diagnosis and treatment of cardiac amyloidosis: A position statement of the ESC Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2021;42(16):1554–1568.
Fotiou D, Dimopoulos MA, Kastritis E. Systemic AL Amyloidosis: Current approaches to diagnosis and management. Hema Sphere. 2020; 4(4):e454.
Jaccard A, Desport E, Mohty D, Bridoux F. Amylose AL. Rev Médecine Interne. 2015;36(2):89‑97.
Palladini G, Sachchithanantham S, Milani P, Gillmore J, Foli A, Lachmann H, et al. A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis. Blood. 2015;126(5):612‑5.
Ash S, Shorer E, Ramgobin D, Vo M, Gibbons J, Golamari R, et al. Cardiac amyloidosis-a review of current literature for the practicing physician. Clin Cardiol. 2021;44(3):322–331.